Corisin
Based on 1 Customer Validation
Corisin is a pro-apoptotic small peptide produced by Staphylococcus species. Corisin binds to serum albumin to target organs such as the lungs and kidneys, induces cellular senescence, apoptosis and epithelial-mesenchymal transition, and accelerates the progression of organ fibrosis including pulmonary fibrosis and diabetic renal fibrosis. Corisin levels are closely associated with coronavirus disease 2019 (COVID-19), diabetic chronic kidney disease (CKD), non-diabetic CKD, and idiopathic pulmonary fibrosis (IPF).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.45%
- CAS No.: 2651277-02-8
- Formule: C84H133N25O28S
- Masse moléculaire:1973.17
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Corisin (48 h) significantly increases phosphatidylserine externalization in human umbilical vein endothelial cells, and this effect is blocked by anti-Corisin monoclonal antibodies[1].
Corisin (5 μM; 24 h) significantly enhances tissue factor activity in A549 alveolar epithelial cells, THP-1 monocytes and human umbilical vein endothelial cells, and this effect is reversed by anti-Corisin monoclonal antibody or anti-TF antibody[1].
Corisin (5 μM; 24 h) significantly reduces thrombomodulin activity in A549 alveolar epithelial cells, THP-1 monocytes and human umbilical vein endothelial cells, and this effect is reversed by anti-Corisin monoclonal antibodies[1].
Corisin (20-40 μg/mL; 24-48 h) promotes apoptosis, disrupts cell cycle progression and reduces proliferative activity in normal human renal proximal tubular epithelial cells, human Caki-2 renal tubular epithelial cells and normal human podocytes, while anti-Corisin monoclonal antibodies inhibit these effects[2].
Corisin (20-40 μg/mL; 48 h) induces cellular senescence in human Caki-2 renal tubular epithelial cells, normal human primary renal tubular epithelial cells, and normal human primary podocytes, which is characterized by increased senescence-associated β-galactosidase activity, altered expression of senescence marker genes, and abnormal nuclear morphology. This effect is inhibited by anti-Corisin monoclonal antibodies[2].
Corisin (20-40 μg/mL; 48 h) induces epithelial-mesenchymal transition in human normal primary podocytes and human normal primary renal proximal tubular epithelial cells, which is characterized by changes in cell morphology and upregulated expression of mesenchymal marker genes, while anti-corisin monoclonal antibodies inhibit these effects[2].
Stimulation of primary human renal proximal tubular epithelial cells with Corisin (20 μg/mL; 24 h) activates pathways associated with DNA damage response, cellular senescence, senescence-associated secretory phenotype, and myofibroblast-like differentiation[2].
Corisin (0.5-50 μM; 16-48 h) induces dose-dependent apoptosis in A549 alveolar epithelial cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549 alveolar epithelial cells
-
Concentration:0.5 μM, 5 μM, 50 μM (48 h); 5 μM (16 h)
-
Incubation Time:48 h (0.5 μM, 5 μM, 50 μM); 16 h (5 μM)
-
Result:Induced apoptosis in a dose-dependent manner.
Increased Annexin V-positive cells to 13.7% at 0.5 μM, 21.1% at 5 μM, and 22.7% at 50 μM, all significantly higher than the control 6.2%.
Confirmed apoptotic morphology via transmission electron microscopy at 5 μM.
Corisin (administered intratracheally; once daily for 2 consecutive days) induces acute exacerbation of pulmonary fibrosis in TGFβ1 TG mice, which is characterized by significant increases in pulmonary inflammation, collagen deposition, levels of profibrotic mediators, and epithelial cell apoptosis[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:TGFβ1 transgenic (female, 9 weeks old)[2]
-
Dosage:5 mg/kg
-
Administration:i.p.; thrice weekly; 2 weeks
-
Result:Elevated urinary levels of corisin, albumin, and albumin-to-creatinine ratio significantly compared to scrambled peptide-treated mice.
Elevated plasma blood urea nitrogen (BUN) and urinary liver-type fatty acid-binding protein (L-FABP) levels significantly compared to scrambled peptide-treated mice.
Elevated plasma levels of lipopolysaccharide-induced CXC chemokine (LIX/CXCL5), macrophage inflammatory protein-2 (MIP-2), interleukin-1β (IL-1β), platelet-derived growth factor (PDGF), tissue factor (TF), and plasminogen activator inhibitor-1 (PAI-1) significantly compared to scrambled peptide-treated mice.
Increased mean circulating corisin levels to 2.2-fold higher than those in diabetic CKD patients and 1.6-fold higher than those in diabetic TGFβ1 transgenic mice.
Increased renal fibrotic changes significantly compared to scrambled peptide-treated mice.
Chemical Information
-
CAS No. 2651277-02-8
-
Appearance Solid
-
Masse moléculaire 1973.17
-
Formule C84H133N25O28S
-
Color White to off-white
-
Sequence
Ile-Val-Met-Pro-Glu-Ser-Ser-Gly-Asn-Pro-Asn-Ala-Val-Asn-Pro-Ala-Gly-Tyr-Arg
-
Sequence Shortening
IVMPESSGNPNAVNPAGYR
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvant et solubilité
DMSO : 25 mg/mL (12.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (1.27 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Tsuruga T, et al. Role of microbiota-derived corisin in coagulation activation during SARS-CoV-2 infection. J Thromb Haemost. 2024;22(7):1919-1935. [Content Brief]
[2]. Yasuma T, et al. Microbiota-derived corisin accelerates kidney fibrosis by promoting cellular aging. Nat Commun. 2025;16(1):7591. Published 2025 Aug 25. [Content Brief]
[3]. D'Alessandro-Gabazza CN, et al. A Staphylococcus pro-apoptotic peptide induces acute exacerbation of pulmonary fibrosis. Nat Commun. 2020;11(1):1539. Published 2020 Mar 24. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.5068 mL | 2.5340 mL | 5.0680 mL | 12.6700 mL |
| 5 mM | 0.1014 mL | 0.5068 mL | 1.0136 mL | 2.5340 mL | |
| 10 mM | 0.0507 mL | 0.2534 mL | 0.5068 mL | 1.2670 mL |
Corisin Related Classifications
HY-P11178 Related Classifications
Powered by Bioz